Citations

Clear

4207 citation(s) found for "Chen, Yu".

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
Chen, Alice P. , Ji, Jiuping , Zhang, Yiping , Ames, Matthew M. , Jia, Lee , Weil, Marcie, Speranza, Giovanna, Murgo, Anthony J., Kinders, Robert J. , Wang, Lihua , Parchment, Ralph E. , Carter, John , Stotler, Howard, Rubinstein, Larry , Hollingshead, Melinda G. , Melillo, Giovanni, Bonner, William, Tomaszewski, Joseph E. , Doroshow, James H. , Kummar, Shivaani , Reid, Joel M. , Pommier, Yves G. , Rubinstein, Larry V

Mayo Clinic

Cancer Research | July 28, 2011 | Volume: 71 | Issue: 17 | Pages: 5626-5634

10.1158/0008-5472.can-11-1227 | PMID 21795476 Get It

Abstract A phase I trial of ABT-888 (veliparib), a PARP inhibitor, in combination with topotecan, a topoisomerase I–targeted agent, was carried out to determine maximum tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of the combination in patients with refractory solid tumors and lymphomas. Varying schedules and doses of intravenous topotecan in combination with ABT-888 (10 mg) administered orally twice a day (BID) were evaluated. Plasma and urine pharmacokinetics were assessed and levels of poly(ADP-ribose) (PAR) and the DNA damage marker γH2AX were measured in tumor and peripheral blood mononuclear cells (PBMC). Twenty-four patients were enrolled. Significant myelosuppression limited the ability to coadminister ABT-888 with standard doses of topotecan, necessitating dose reductions. Preclinical studies using athymic mice carrying human tumor xenografts also informed schedule changes. The MTD was established as topotecan 0.6 mg/m2/d and ABT-888 10 mg BID on days one to five of 21-day cycles. Topotecan did not alter the pharmacokinetics of ABT-888. A more than 75% reduction in PAR levels was observed in 3 paired tumor biopsy samples; a greater than 50% reduction was observed in PBMCs from 19 of 23 patients with measurable levels. Increases in γH2AX response in circulating tumor cells (CTC) and PBMCs were observed in patients receiving ABT-888 with topotecan. We show a mechanistic interaction of a PARP inhibitor, ABT-888, with a topoisomerase I inhibitor, topotecan, in PBMCs, tumor, and CTCs. Results of this trial reveal that PARP inhibition can modulate the capacity to repair topoisomerase I–mediated DNA damage in the clinic. Cancer Res; 71(17); 5626–34. ©2011 AACR.
Comparison of Adenoviruses as Oncolytics and Cancer Vaccines in an Immunocompetent B Cell Lymphoma Model
Chen, Christopher Y. , May, Shannon M., Barry, Mary E., Barry, Mary E., Barry, Michael A., Barry, Michael A., Barry, Michael A. , Weaver, Eric A. , Barry, Mary E., Barry, Michael A., Barry, Michael A., Weaver, Eric A , Barry, Michael A

Mayo Clinic

Human Gene Therapy | July 19, 2011 | Volume: 22 | Issue: 9 | Pages: 1095-1100

10.1089/hum.2011.071 | PMID 21770794 Get It

Nuclear translocation of AMPK-α1 potentiates striatal neurodegeneration in Huntington’s disease
Ju, Tz‐Chuen , Lin, Jiun‐Tsai, Chang, Ching‐Pang , Chang, Wei-Cheng, Kang, Jheng-Jie, Sun, Cheng‐Pu , Tao, Mi‐Hua , Tu, Pang‐Hsien , Chang, Chen , Dickson, Dennis W. , Chern, Yijuang , Chen, Huimei , Dickson, Dennis W

Mayo Clinic

Journal of Cell Biology | July 18, 2011 | Volume: 194 | Issue: 2 | Pages: 209-227

10.1083/jcb.201105010 | PMID 21768291 Get It

Adenosine monophosphate–activated protein kinase (AMPK) is a major energy sensor that maintains cellular energy homeostasis. Huntington’s disease (HD) is a neurodegenerative disorder caused by the expansion of CAG repeats in the huntingtin (Htt) gene. In this paper, we report that activation of the α1 isoform of AMPK (AMPK-α1) occurred in striatal neurons of humans and mice with HD. Overactivation of AMPK in the striatum caused brain atrophy, facilitated neuronal loss, and increased formation of Htt aggregates in a transgenic mouse model (R6/2) of HD. Such nuclear accumulation of AMPK-α1 was activity dependent. Prevention of nuclear translocation or inactivation of AMPK-α1 ameliorated cell death and down-regulation of Bcl2 caused by mutant Htt (mHtt). Conversely, enhanced expression of Bcl2 protected striatal cells from the toxicity evoked by mHtt and AMPK overactivation. These data demonstrate that aberrant activation of AMPK-α1 in the nuclei of striatal cells represents a new toxic pathway induced by mHtt.
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells
Leon, Johanny Tonos De, Iwai, Aki, Féau, Clémentine, Garcia, Yenni A., Balsiger, Heather A., Storer, Cheryl L., Suro, Raquel M., Garza, Kristine M. , Kim, Yeong Sang, Chen, Yu , Ning, Yang‐Min, Fletterick, Robert J. , Guy, R. Kiplin , Trepel, Jane B. , Neckers, Leonard Μ. , Cox, Marc B. , Lee, Sunmin , Riggs, Daniel L.

Mayo Clinic

Proceedings of the National Academy of Sciences | July 5, 2011 | Volume: 108 | Issue: 29 | Pages: 11878-11883

10.1073/pnas.1105160108 | PMID 21730179 Get It

Drugs that target novel surfaces on the androgen receptor (AR) and/or novel AR regulatory mechanisms are promising alternatives for the treatment of castrate-resistant prostate cancer. The 52 kDa FK506 binding protein (FKBP52) is an important positive regulator of AR in cellular and whole animal models and represents an attractive target for the treatment of prostate cancer. We used a modified receptor-mediated reporter assay in yeast to screen a diversified natural compound library for inhibitors of FKBP52-enhanced AR function. The lead compound, termed MJC13, inhibits AR function by preventing hormone-dependent dissociation of the Hsp90-FKBP52-AR complex, which results in less hormone-bound receptor in the nucleus. Assays in early and late stage human prostate cancer cells demonstrated that MJC13 inhibits AR-dependent gene expression and androgen-stimulated prostate cancer cell proliferation.
Dynamic Postprandial Hepatic Stiffness Augmentation Assessed With MR Elastography in Patients With Chronic Liver Disease
Yin, Meng , Talwalkar, Jayant A., Glaser, Kevin J. , Venkatesh, Sudhakar K. , Chen, Jun , Manduca, Armando , Ehman, Richard L. , Venkatesh, Sudhakar K , Yin, Meng

Mayo Clinic

American Journal of Roentgenology | July 1, 2011 | Volume: 197 | Issue: 1 | Pages: 64-70

10.2214/ajr.10.5989 | PMID 21701012 Get It

Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients
Huang, R. Stephanie , Johnatty, Sharon E. , Gamazon, Eric R. , Im, Hae Kyung , Ziliak, Dana, Zhang, Wei , Kistner, Emily O., Chen, Peixian , Beesley, Jonathan, Mi, Shuangli , O’Donnell, Peter H. , Fraiman, Yarden S. , Das, Soma , Cox, Nancy J. , Lu, Yi , MacGregor, Stuart , Goode, Ellen L. , Vierkant, Robert A. , Høgdall, Estrid , Kjær, Susanne K. , Jensen, Allan , Moysich, Kirsten B., Grasela, Matthew, Odunsi, Kunle , Brown, Robert , Paul, Jim, Lambrechts, Diether , Despierre, Evelyn, Vergote, Ignace , Gross, Jenny , DeFazio, Anna , Chenevix‐Trench, Georgia , Dolan, M. Eileen , Lambrechts, Diether , Duan, Shiwei , Fridley, Brooke L. , Paul, Jim, Karlan, Beth Y. , Fazio, Anna de , Lambrechts, Diether , Kjaer, Susanne K , Jensen, Allan , Vierkant, Robert A , Moysich, Kirsten , Brown, Robert , Lambrechts, Diether , Lu, Yi , MacGregor, Stuart , Chenevix-Trench, Georgia , Høgdall, Estrid , Huang, R Stephanie , Im, H K

Mayo Clinic

Clinical Cancer Research | June 25, 2011 | Volume: 17 | Issue: 16 | Pages: 5490-5500

10.1158/1078-0432.ccr-11-0724 | PMID 21705454 Get It

Abstract Purpose: Cell-based approaches were used to identify genetic markers predictive of patients' risk for poor response prior to chemotherapy. Experimental Design: We conducted genome-wide association studies (GWAS) to identify single-nucleotide polymorphisms (SNP) associated with cellular sensitivity to carboplatin through their effects on mRNA expression using International HapMap lymphoblastoid cell lines (LCL) and replicated them in additional LCLs. SNPs passing both stages of the cell-based study were tested for association with progression-free survival (PFS) in patients. Phase 1 validation was based on 377 ovarian cancer patients receiving at least four cycles of carboplatin and paclitaxel from the Australian Ovarian Cancer Study (AOCS). Positive associations were then assessed in phase 2 validation analysis of 1,326 patients from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Results: In the initial GWAS, 342 SNPs were associated with carboplatin-induced cytotoxicity, of which 18 unique SNPs were retained after assessing their association with gene expression. One SNP (rs1649942) was replicated in an independent LCL set (Bonferroni adjusted P < 0.05). It was found to be significantly associated with decreased PFS in phase 1 AOCS patients (Pper-allele = 2 × 10−2), with a stronger effect in the subset of women with optimally debulked tumors (Pper-allele = 4 × 10−3). rs1649942 was also associated with poorer overall survival in women with optimally debulked tumors (Pper-allele = 9 × 10−3). However, this SNP was not significant in phase 2 validation analysis with patients from numerous cohorts. Conclusion: This study shows the potential of cell-based, genome-wide approaches to identify germline predictors of treatment outcome and highlights the need for extensive validation in patients to assess their clinical effect. Clin Cancer Res; 17(16); 5490–500. ©2011 AACR.
Ethical and Methodological Issues in Pedigree Stroke Research
Worrall, Bradford B. , Chen, Donna T. , Meschia, James F.

Mayo Clinic

Stroke | June 17, 2011 | Volume: 32 | Issue: 6 | Pages: 1242-1249

10.1161/01.str.32.6.1242 | PMID 11387482 Get It

Background —Stroke is a complex genetic disorder with a variable phenotype. Investigations of heritable factors in complex genetic disorders use pedigree and genetic techniques, which pose different ethical and methodological challenges than those routinely encountered in therapeutic research. Building consensus on acceptable research practices in this field is vital to the success of multicentered collaborations. Summary of Review —We review important ethical and methodological concerns related to the collection, storage, and release of pedigree research information. The human studies aspects of pedigree research are complicated methodologically because individuals can be active or passive participants and pedigrees can be proband derived, partially validated, or fully validated. Current research ethics frameworks do not work well outside of a dyadic researcher-subject relationship. Privacy and confidentiality for family members must be considered in pedigree research. Investigators should anticipate potential conflicts of interest among family members when designing a pedigree research protocol. Conclusions —We propose a “proband-initiated contact” methodology in which the proband or the proband’s designate allows identification of potential families without breaching the privacy of individuals in the family. In situations in which family history data are collected without direct contact between researchers and individuals in the proband’s family, an Institutional Review Board may waive consent by family members after appropriate review of the protocol and application of rules for granting waivers of consent. Certificates of Confidentiality should be considered.
Adventitial Expression of Recombinant eNOS Gene Restores NO Production in Arteries Without Endothelium
Tsutsui, Masato , Chen, Alex F.Y., Crotty, Thomas B., Katušić, Zvonimir S. , O’Brien, Timothy

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | June 17, 2011 | Volume: 18 | Issue: 8 | Pages: 1231-1241

10.1161/01.atv.18.8.1231 | PMID 9714129 Get It

Abstract—The current study was designed to determine the effect of recombinant endothelial nitric oxide synthase (eNOS) gene expression on endothelium-dependent relaxations to bradykinin in isolated canine basilar, coronary, or femoral arteries. Arterial rings were exposed ex vivo (30 minutes at 37°C) to an adenoviral vector encoding either the eNOS gene (AdCMVeNOS) or the β-galactosidase reporter gene (AdCMVβ-Gal). Twenty-four hours after transduction, transgene expression was evident mainly in the adventitia. Expression of recombinant proteins was much higher in basilar arteries than in coronary or femoral arteries. Rings of control, AdCMVβ-Gal, and AdCMVeNOS arteries with and without endothelium were suspended for isometric tension recording. Levels of cGMP were measured by radioimmunoassay. In AdCMVeNOS basilar arteries with endothelium, relaxations to low concentrations of bradykinin (3×10−11to 10−9mol/L) were significantly augmented. In contrast, in coronary and femoral arteries with endothelium, AdCMVeNOS transduction did not affect relaxations to bradykinin. Removal of the endothelium abolished bradykinin-induced relaxations in control and AdCMVβ-Gal basilar arteries. However, in basilar arteries transduced with AdCMVeNOS even when the endothelium was removed, stimulation with bradykinin (3×10−11to 10−9mol/L) caused relaxations as well as increases in cGMP production. The relaxations to bradykinin were completely blocked by an NOS inhibitor,NG-nitro-l-arginine methyl ester. Electron microscopic analysis revealed that recombinant eNOS protein was expressed in fibroblasts of the basilar artery adventitia. These results suggest that genetically modified adventitial fibroblasts may restore production of NO in cerebral arteries without endothelium. Our findings support a novel concept in vascular biology that fibroblasts in the adventitia may play a role in the regulation of vascular tone after successful transfer and expression of recombinant eNOS gene.
Inherited Variants in Mitochondrial Biogenesis Genes May Influence Epithelial Ovarian Cancer Risk
Permuth‐Wey, Jennifer, Chen, Y. Ann , Tsai, Ya-Yu, Chen, Zhihua , Qu, Xiaotao , Lancaster, Johnathan M., Stockwell, Heather, Dagne, Getachew , Iversen, Edwin S., Barnholtz‐Sloan, Jill S. , Cunningham, Julie M. , Vierkant, Robert A. , Sutphen, Rebecca , McLaughlin, John, Narod, Steven A., Goode, Ellen L. , Schildkraut, Joellen M. , Fenstermacher, David, Phelan, Catherine M., Sellers, Thomas A. , Risch, Harvey A. , Fridley, Brooke L. , McLaughlin, John, Vierkant, Robert A , Barnholtz-Sloan, Jill S

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 7, 2011 | Volume: 20 | Issue: 6 | Pages: 1131-1145

10.1158/1055-9965.epi-10-1224 | PMID 21447778 Get It

Abstract Background: Mitochondria contribute to oxidative stress, a phenomenon implicated in ovarian carcinogenesis. We hypothesized that inherited variants in mitochondrial-related genes influence epithelial ovarian cancer (EOC) susceptibility. Methods: Through a multicenter study of 1,815 Caucasian EOC cases and 1,900 controls, we investigated associations between EOC risk and 128 single nucleotide polymorphisms (SNPs) from 22 genes/regions within the mitochondrial genome (mtDNA) and 2,839 nuclear-encoded SNPs localized to 138 genes involved in mitochondrial biogenesis (BIO, n = 35), steroid hormone metabolism (HOR, n = 13), and oxidative phosphorylation (OXP, n = 90) pathways. Unconditional logistic regression was used to estimate OR and 95% CI between genotype and case status. Overall significance of each gene and pathway was evaluated by using Fisher's method to combine SNP-level evidence. At the SNP level, we investigated whether lifetime ovulation, hormone replacement therapy (HRT), and cigarette smoking were confounders or modifiers of associations. Results: Interindividual variation involving BIO was most strongly associated with EOC risk (empirical P = 0.050), especially for NRF1, MTERF, PPARGC1A, ESRRA, and CAMK2D. Several SNP-level associations strengthened after adjustment for nongenetic factors, particularly for MTERF. Statistical interactions with cigarette smoking and HRT use were observed with MTERF and CAMK2D SNPs, respectively. Overall variation within mtDNA, HOR, and OXP was not statistically significant (empirical P > 0.10). Conclusion: We provide novel evidence to suggest that variants in mitochondrial biogenesis genes may influence EOC susceptibility. Impact: A deeper understanding of the complex mechanisms implicated in mitochondrial biogenesis and oxidative stress may aid in developing strategies to reduce morbidity and mortality from EOC. Cancer Epidemiol Biomarkers Prev; 20(6); 1131–45. ©2011 AACR.
Simultaneous Phenotyping and Quantification of α-1-Antitrypsin by Liquid Chromatography–Tandem Mass Spectrometry
Snyder, Melissa R, Zhu, Yi , Tostrud, Linda J., Benson, Linda M., Katzmann, Jerry A., Bergen, H. Robert, Chen, Yuhong , Snyder, Melissa R, Zhu, Yi

Mayo Clinic

Clinical Chemistry | June 3, 2011 | Volume: 57 | Issue: 8 | Pages: 1161-1168

10.1373/clinchem.2011.163006 | PMID 21636698 Get It

BACKGROUNDα-1-Antitrypsin (A1AT) deficiency results from a genetic disorder at 2 common loci. Diagnosis requires quantification of A1AT and subsequent identification of the specific variant. The current algorithm of laboratory testing for the diagnosis of A1AT deficiency uses a combination of quantification (nephelometry), genotyping, and/or phenotyping. We developed a multiple reaction monitoring liquid chromatography–tandem mass spectrometry (LC-MS/MS) method for simultaneous quantification of A1AT and identification of the 2 most common deficiency alleles present in 95% of the patients with A1AT deficiency.METHODSSerum samples (n = 40) were digested with trypsin, and appropriate 13C/15N-labeled standard peptides were added. We performed LC-MS/MS analysis with a 0.5- by 150-mm C18 column and H2O:acetonitrile:n-propanol:formic acid (A:98:1:1:0.2 and B:10:80:10:0.2; flow 12 μL/min) mobile phase in positive ion mode on a TSQ Quantum triple quadrupole MS system. We measured the A1AT concentration by comparison to a calibration curve and determined the phenotype by the presence or absence of variant peptides. We compared the results to the current phenotyping assay by isoelectric focusing (IEF) and the immunonephelometry quantitative assay.RESULTSFor A1AT allele detection, in 39 of 40 samples the LC-MS/MS results were identical to those obtained by IEF gel electrophoresis. The single discrepant result was rerun by IEF at a lower dilution, and the results were in concordance. The A1AT quantification by LC-MS/MS also compared favorably with nephelometry.CONCLUSIONSThe LC-MS/MS method correlates well with current phenotyping and nephelometric assays and has the potential to improve the laboratory diagnosis of genetic A1AT deficiency.